Key Highlights
- Shares are trading down 7.28% at $62.32 versus a prior close of $67.21.
- Third-quarter Revenue of $206.7 million and EPS of $0.14 topped estimates.
- 2026 revenue guidance was narrowed to $850 million to $860 million.
Inspire Medical Systems (NYSE:INSP) shares are trading down 7.28% at $62.32 today after a third-quarter report that beat consensus but offered a cautious outlook. The stock sits within a 52-week range of $38.91 to $147.03, and the weakness looks stock-specific, with the broader healthcare sector little changed.
Inspire Medical Systems is a Golden Valley, Minnesota-based medical technology company founded in 2007 as a spin-out from Medtronic. It develops and commercializes minimally invasive therapies for moderate to severe obstructive sleep apnea, led by the Inspire system, an implantable, closed-loop neurostimulation therapy that delivers mild hypoglossal nerve stimulation to keep the airway open. It reported about $912 million in revenue in 2025, up 14%.
Beat on Revenue and EPS, but Guidance Trimmed at the Top End
Third-quarter revenue was $206.7 million, down 7.9% year over year and up 3% sequentially, against estimates of $204.3 million. Adjusted EPS was $0.14 against $0.10 expected, gross Margin was 86% and Operating Cash Flow was $46.4 million. Cash and investments totaled $453.1 million with no debt. International underperformed due to destocking in Germany.
Full-year 2026 revenue guidance was narrowed to $850 million to $860 million, cutting the top end from $875 million, with adjusted Operating Margin of 4.5% to 5.5% and adjusted diluted EPS of $1.20 to $1.40. Management expects another significant sequential revenue increase in the fourth quarter in both the U.S. and international markets.
2027 Growth Seen at Low Single Digits
For 2027, management expects low single-digit full-year revenue growth, slightly below the roughly 4% consensus, supported by a more stable coding environment, market growth, Project Horizon investments and higher battery replacement revenue. Project Horizon created about $30 million of annualized growth Investment capacity, directed to a net 40 added field support roles in high-potential markets, targeted Marketing and patient pathway improvements.
Capital expenditures are expected at $35 million to $40 million, and coding and reimbursement headwinds are estimated at about $120 million for the year.
Coding Clarity and Analyst Reactions Are Mixed
A stable temporary billing framework is in place, and the final 2027 OPPS rule is expected later this week. A new Category I CPT code for single-lead hypoglossal nerve stimulation takes effect on January 1, 2028. Wells Fargo, Piper Sandler, Baird and JPMorgan raised targets, while Truist and Barclays cut theirs, with Barclays at $62. Inspire 6, a firmware upgrade adding automatic sleep detection, could be submitted to the FDA next year.
OPPS Rule and Inspire 6 Filing Are the Next Markers
The final 2027 OPPS rule later this week and a potential Inspire 6 FDA submission next year are the next items for investors. Management said coding and reimbursement headwinds are easing, even as the stock sits more than 55% below its 52-week high.






Please wait processing your request...